China’s biosimilar development engine is supercharged and running on octane, a recent report said.
China has lagged in the adoption of anticancer biosimilars, but a huge number of agents in development suggest an “incoming wave” of these agents is about to hit, according to authors of a recent study.
Just 2 anticancer biosimilars were approved in China by the end of 2019, but the country has 23.9% of the global cancer burden. The turning point in China could occur very soon, the authors said, noting that 54 anticancer biosimilars representing 7 reference products are under clinical development in mainland China, 3 are involved in new drug application reviews, and 27 are in late-phase efficacy comparative studies.
These findings were included in a report of biosimilar adoption in 40 countries with 78.1% of the worldwide cancer incidence. China’s biosimilar development engine is supercharged and running on octane, the report said.
Visit The Center for Biosimilars for the full story.